Changes in survival among people with AIDS in Lazio, Italy from 1993 to 1998

AIDS

Volumn 13, Issue 15, 1999, Pages 2125-2131

  Porta, Daniela ^a   Rapiti, Elisabetta ^a   Forastiere, Francesco ^a   Pezzotti, Patrizio ^b   Perucci, Carlo A ^a  

^a DEPARTMENT OF EPIDEMIOLOGY   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

AIDS; Longitudinal study; Mortality; Surveillance; Survival

Indexed keywords

CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; FEMALE; FOLLOW UP; GENDER; HUMAN; ITALY; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK; SURVIVAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; FEMALE; HUMANS; ITALY; LONGITUDINAL STUDIES; MALE; POPULATION SURVEILLANCE; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS;

EID: 0032750955     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199910220-00016     Document Type: Article

References (26)

1. HIV/AIDS surveillance in Europe. European Centre for the Epidemiological Monitoring of AIDS Quarterly Report 52. Saint Maurice, France, 1996.
2. Gebhardt M, Rickenbach M, Egger M, and the Swiss HIV Cohort Study. Impact of antiretroviral combination therapies on AIDS surveillance reports in Switzerland. AIDS 1998, 12:1195-1201.
3. Fleming PL, Ward JW, Karon JM, Hanson DL, de Cock KM. Declines in AIDS incidence and deaths in the USA: a signal change in the epidemic. AIDS 1998, 12(Suppl A):S55-S61.
4. Delta Coordinating Committee. Delta: a randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected patients. Lancet 1996, 348:283-291.
5. CAESAR Coordinating Committee. Randomized trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAE-SAR trial. Lancet 1997; 349:1413-1421.
6. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogs plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
7. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
8. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral-viral combination therapies in HIV-infected patients in Switzerland: prospective multicenter study. Br Med J 1997, 315:1194-1199.
9. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. J Am Med Assoc 1998, 279:450-454.
10. Mocroft A, Vella S, Benfield T, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998, 352:1725-1730.
11. Detels R, Mujoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. J Am Med Assoc 1998, 280:1487-1503.
12. Pezzotti P, Napoli PA, Acciai S, et al. Increasing survival time after AIDS in Italy: the role of new combination antiretroviral therapies. AIDS 1999, 13:249-255.
13. HIV/AIDS surveillance in Europe. European Centre for the Epidemiological Monitoring of AIDS. Quarterly Report 46. Saint Maurice, France, 1995.
14. Conti S, Farchi G, Galletti A, et al. La notifica della mortalità per AIDS in Italia (1992): qualità della certificazione e sottonotifica. Giornale Italiano dell'AIDS 1997, 8:12-16.
15. Ministero della Sanità. Linee guida sulla terapia dell'infezione da HIV. Circolare n. 18, 23 Dicembre 1996, Gazzetta Uffiiciale della Repubblica Italiana- Serie Generale-8 Gennaio Rome, Italy 1997.
16. Lagorio S, Forastiere F, Perucci CA, et al. Cause of death ascertainment in follow-up studies: comparison of procedures available in Italy. Epidemiol Prev 1987, 31:57-61.
17. Alioum A, Leroy V, Commenges D, Dabis F, Salamon R. Effect of gender, age, transmission category, and antiretroviral therapy on the progression of human immunodeficiency virus infection using multistate Markov models. Epidemiology 1998, 9:605-612.
18. Law MG, de Winter L, McDonald A, Cooper DA, Kaldor JM. AIDS diagnoses at higher CD4 counts in Australia following the introduction of highly active antiretroviral treatment. AIDS 1999, 13:263-269.
19. Chaisson RE, Kerly JC, Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med 1995, 333:751-756.
20. Whitmore-Overton SE, Tillet HE, Evans BG, Allardice GM. Improved survival from diagnosis of AIDS in adult cases in the United Kingdom and bias due to reporting delays. AIDS 1993, 7:415-420.
21. Blum S, Singh TP, Gibbons J, et al. Trends in survival among persons with acquired immunodeficiency syndrome in New York City. Am J Epidemiol 1994, 139:351-361.
22. Melnick SL, Sherer R, Louis TA, et al. Survival and disease progression according to gender of patients with HIV infection. The Terry Beirn Community Programs for Clinical Research on AIDS. J Am Med Assoc 1994, 272:1915-1921.
23. Egger M, Twisselmann W, Lederberger B. Differences in progression of HIV infection between men and women. Br Med J 1995, 310:941.
24. Moore RD, Stanton D, Gopalan R, Chaisson RE. Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med 1994, 330:763-768.
25. Hellinger FJ. The use of health services by women with HIV infection. Health Serv Res 1993, 28:543-561.
26. Strathdee SA, Palepu A, Cornelisse PGA, et al. Barriers to use of free antiretroviral therapy in injection drug users. J Am Med Assoc 1998, 280:547-549.